MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy ...
Impact of aromatase inhibitors on mortality and hospitalization costs in patients with breast cancer: A National Inpatient Sample analysis 2020.
CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results